Telangana Sets Sights on Global TechBio Leadership with BioAsia 2026
Hyderabad is poised to become a premier global techbio hub as BioAsia 2026 commences on Tuesday, featuring an impressive roster of international speakers. The event will host Dr Howard Y Chang, Chief Scientific Officer and SVP of Global Research at Amgen, Pushmeet Kohli, VP of Science at Google DeepMind, Prof Bruce Levine, a CAR-T cell therapy pioneer from the University of Pennsylvania, and Madeleine Roach, EVP and Head of Business Operations at Sanofi.
Asia's Largest Life Sciences Platform Expands
The two-day conclave, recognized as Asia's largest platform for the life sciences sector, operates under the theme 'TechBio Unleashed: AI, Automation and the Biology Revolution'. It will be inaugurated by Chief Minister A Revanth Reddy and Industries Minister D Sridhar Babu. This year's edition is set to grow significantly, with delegate participation expected to increase by nearly 25% to 4,000 attendees, up from approximately 3,000 last year. Over 500 companies are participating, reflecting the event's expanding global footprint.
The exhibition area has also expanded to 9,000 square metres, compared to nearly 7,000 square metres in the previous year. More than 175 exhibitors will showcase innovations across pharmaceuticals, biotechnology, medtech, digital health, and advanced manufacturing sectors.
Strategic Focus on AI and Innovation
Life sciences and technology experts will engage in critical deliberations on AI-driven discovery workflows, advanced therapeutic modalities, and the role of automation in scaling manufacturing. These discussions align with Telangana's strategic push to enhance capabilities in biologics, vaccines, bioprocess design, and AI-enabled healthcare.
The speaker lineup includes top executives from global giants such as:
- Novartis
- Eli Lilly
- Thermo Fisher Scientific
- Sanofi
- MSD
- AstraZeneca
- Novo Nordisk
- Olympus Corp
- Miltenyi Biotec
Indian industry leaders from Dr Reddy's Laboratories, Bharat Biotech, Biocon Biologics, and Laurus Labs will also contribute to the conversations.
From Laboratory Discovery to Commercial Execution
Strategic sessions will explore how innovation transitions from laboratory discovery to clinical and commercial execution. Key topics include leveraging AI for speed, efficiency, and decision-making across the value chain, alongside discussions on developing resilient supply networks and fostering cross-border collaboration.
With global capability centres (GCCs) gaining prominence, BioAsia 2026 will feature dedicated plenaries and panel discussions on this theme. Day 2 sessions will focus on building innovation-first GCCs that prioritize AI, R&D, and digital transformation, as well as how healthcare GCCs can translate capabilities into tangible end-patient impact.
Showcasing Entrepreneurship and Breakthrough Technologies
The conclave will highlight entrepreneurship and applied innovation through a Startup Pavilion featuring 40 emerging startups and an Innovation Pavilion with 16 exhibitors presenting breakthrough technologies and R&D advances. Additionally, 22 MSME exhibitors will participate, underscoring the event's commitment to fostering diverse innovation ecosystems.
According to the Telangana government, this year's BioAsia builds upon the next-generation life sciences policy unveiled at the World Economic Forum in Davos. The policy emphasizes sustainability, precision medicine, digital health, and supply chain diversification, positioning Telangana at the forefront of the global techbio revolution.
